Medtronic (NYSE:MDT) is making leadership changes in its diabetes, surgical robotics and cardiac rhythm management operating units, the company said today.
Que Dallara joins the medtech giant as EVP and president of the diabetes business, Mike Marinaro is now the president of surgical robotics and Dr. Kweli Thompson has been appointed as president of cardiac rhythm management at Medtronic.
“The future of medical technology requires strong leadership in data science, artificial intelligence, and robotics, all of which make these three operating unit president roles some of the most important and dynamic leadership opportunities in our industry,” Medtronic Chair and CEO Geoff Martha said in a news release. “These appointments not only strengthen our businesses and build our technology expertise; they also further establish Medtronic as a destination for world-class talent.”
Dallara will join Medtronic’s executive committee on May 2. She was previously president and CEO of Honeywell Connected Enterprise and before that held leadership roles at TE Connectivity and Microsoft.
She succeeds EVP and president of Medtronic’s cardiovascular portfolio and diabetes unit, Sean Salmon, who will focus exclusively on leading the cardiovascular portfolio while supporting Dallara’s transition into her new role.
Marinaro has more than 20 years of experience at Medtronic, most recently leading the cardiac rhythm management operating unit. He will report to EVP and Medical Surgical Portfolio President Bob White.
Marinaro succeeds Megan Rosengarten, who Medtronic said is “taking a planned six-month sabbatical to spend more time with her family with the full support of Medtronic.” Rosengarten led surgical robotics — which includes the company’s Hugo system — for four years
Thompson takes over the cardiac rhythm management unit, where he will report to Salmon.
Thompson previously served as VP and GM of the cardiac resynchronization and defibrillation solutions businesses. He has two decades of experience in business development, clinical research, product marketing, and general management, Medtronic said.